AI assistant
Immuron Ltd — Declaration of Voting Results & Voting Rights Announcements 2014
May 26, 2014
35121_rns_2014-05-26_510b212a-558b-4640-b625-00b0046002c9.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in viewerOpens in your device viewer
==> picture [209 x 45] intentionally omitted <==
IMMURON LIMITED
(ASX: IMC)
Results of General Meeting
Tuesday, 27[th] May 2014
The Company wishes to advise that all resolutions were unanimously carried on show of hands.
In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the General Meeting held today.
| Resolution | Resolution | For | Against | Abstain | Proxy'sDiscretion* | Total ValidProxiesReceived |
|---|---|---|---|---|---|---|
| 1 | Ratification of Prior Issue of UnlistedOptions | 1,435,833,857 | 64,958,931 | 325,415 | 71,149,744 | 1,571,942,532 |
| 2 | Approve the Issue of Shares to GrandlodgePtyltd or its Nominee | 919,873,081 | 55,040,599 | 526,204,523 | 71,149,744 | 1,046,063,424 |
| 3 | Approve the Issue of Unlisted Options toReza Moussakhani or his Nominee | 1,445,736,189 | 55,040,599 | 291,415 | 71,199,744 | 1,571,976,532 |
| 4 | Adoption of New Constitution | 1,259,045,749 | 54,847,259 | 187,175,195 | 71,199,744 | 1,385,092,752 |
- The Chairman voted undirected proxies in his control in favour of all resolutions.
For and on behalf of the Board;
==> picture [97 x 37] intentionally omitted <==
Peter Vaughan Company Secretary
About Immuron Limited
Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron’s technology platform products all have a very high safety profile. The company’s current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers’ diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).
Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143
www.immuron.com ABN: 80 063 114 045
Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735